Barclays PLC Day One Biopharmaceuticals, Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 141,452 shares of DAWN stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
141,452
Previous 135,373
4.49%
Holding current value
$1.28 Million
Previous $1.89 Million
4.98%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding DAWN
# of Institutions
176Shares Held
77.8MCall Options Held
139KPut Options Held
253K-
Atlas Venture Life Science Advisors, LLC6.43MShares$58.3 Million13.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.85MShares$53 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$52.1 Million1.18% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$44.2 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$41.1 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $666M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...